Reportlinker Adds Cancer Colorectal Cancer or Colon Cancer

Friday, November 13, 2009 General News J E 4
NEW YORK, Nov. 12 announces that a new market research report is available in its catalogue.

Cancer Colorectal Cancer or Colon Cancer

Life Science Analytics', Cancer Colorectal Cancer or Colon Cancer contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of colorectal cancer or colon cancer drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics' Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

To order this report:

Cancer Colorectal Cancer or Colon Cancer

More market research reports here!

-- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas. -- Keep track of your competitors and partners by better understanding their product pipeline. -- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas. -- Maintain a critical competitive advantage.

SOURCE Reportlinker


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Milestone Scientific Announces Third Quarter 2009 ...
Reportlinker Adds Cardiovascular and Circulatory S...